Introduction And Pathogenesis

Atopic dermatitis represents an acute, subacute, or chronic relapsing endogenous eczema.
Characterized predominantly by intensely dry skin and recurrent, pruritic, symmetric dermatitic lesions.
Driven by a combination of underlying genetic susceptibility and complex immunological changes.
Pathogenesis features a significantly heightened immunoglobulin E immune response.

Clinical Manifestations And Age-Specific Patterns

Cutaneous lesions typically manifest in infancy, beginning at any time after 3 months of age.
The disease progresses through distinct clinical patterns based directly on the patient's age.

Disease Phase	Typical Age Range	Distinctive Clinical Morphology And Distribution
Infantile Pattern	3 months to 18 months.	Manifests primarily as highly pruritic, erythematous papulovesicles. Lesions localize prominently on the face, forming crusted erythematous plaques. Eruption may rapidly become generalized. Clears completely by 18 months in 40 percent of patients. Evolves into childhood pattern in the remaining patients.
Childhood Pattern	18 months through late childhood.	Characterized heavily by dry, severely excoriated plaques. Lesions localize characteristically within the major flexures, notably the antecubital and popliteal fossae.
Adult Pattern	Adolescence and adulthood.	Dominated extensively by chronic flexural lichenification.

Diagnosis relies fundamentally on established clinical criteria rather than specific laboratory tests.
Definitive diagnosis strictly requires the presence of at least three major features and at least three minor features.

Intense and persistent pruritus.
Typical morphology and distribution pattern. This includes facial and extensor involvement in infants and children, and flexural lichenification in adults.
Chronic or chronically relapsing dermatitic course.
Personal or family history of atopy. Associated atopic disorders include asthma, allergic rhinitis, and atopic dermatitis.

Category	Specific Minor Diagnostic Features
Ocular And Facial	Anterior subcapsular cataracts, recurrent conjunctivitis, keratoconus, facial pallor or erythema, orbital darkening.
Cutaneous Abnormalities	Ichthyosis, palmar hyperlinearity, keratosis pilaris, pityriasis alba, white dermographism, xerosis.
Specific Dermatitis Variants	Cheilitis, nonallergic irritant hand dermatitis, nipple dermatitis.
Triggers And Systemic	Elevated serum levels of immunoglobulin E, immediate type 1 skin test reactivity, susceptibility to cutaneous infections, severe itching when sweating, established food intolerance, wool intolerance.

Disease Entity	Distinguishing Clinical Features
Infantile Seborrheic Dermatitis	Onset occurs earlier, typically in the first 4 weeks of life. Manifests with yellow-orange, greasy scales and crusts predominating on the scalp (cradle cap). Usually nonpruritic, unlike atopic dermatitis. Resolves spontaneously by 12 weeks.
Irritant Contact Dermatitis	Often difficult to distinguish clinically. Typically results from prolonged or repetitive contact with specific chemical or mechanical irritants. Children with atopic dermatitis exhibit an increased propensity for developing concurrent irritant dermatitis.
Nummular Eczema	Characterized by distinct coin-shaped, weeping, severely pruritic plaques. Lacks the typical flexural distribution. May present either as an independent disorder or as an atypical morphologic manifestation in a patient with underlying atopic dermatitis.
Psoriasis	Features well-demarcated, bright red plaques surmounted by thick silvery scale. Predilection for extensor surfaces rather than flexures.

Intensely excoriated skin strongly predisposes the patient to secondary cutaneous infections.
Bacterial superinfections occur frequently.
Viral infections may spread explosively across the compromised epidermal barrier.
Disseminated viral infections include herpes simplex and widespread molluscum contagiosum.
Fungal superinfections represent another significant complication.

Therapy mandates educating caretakers regarding the inherent chronicity of the disease.
Children must avoid direct cutaneous contact with known irritants, particularly woolens and harsh chemicals.
Implement rigorous environmental measures targeting house dust mite reduction.
Utilize protective barriers on pillows and mattresses, and enforce regular vacuuming.
Breastfeeding is strongly encouraged as it may decrease the infant's subsequent chance of developing the disease.
Strict dietary restrictions remain generally unwarranted unless a specific food allergy is proven.
Routine vaccinations carry absolutely no contraindication, except for influenza and yellow fever vaccines in children demonstrating specific severe egg allergy.

Utilize only mild, non-irritating soaps and gentle cleansing lotions during bathing.
Apply liberal amounts of moisturizers or emollients, such as petrolatum, immediately following bathing to trap moisture.

Treat acute weeping lesions actively utilizing wet dressings combined with topical corticosteroids.
Manage chronic lichenified plaques through aggressive hydration followed by emollient application and short courses of topical corticosteroids.
Utilize the least potent topical corticosteroid necessary to adequately control clinical symptoms.
Avoid applying potent topical corticosteroids to delicate facial or genital skin.
Employ topical immunomodulators, specifically tacrolimus and pimecrolimus.
These steroid-sparing agents provide excellent anti-inflammatory and antipruritic actions.
Administer oral antihistaminics consistently to break the destructive itch-scratch cycle.
Prescribe appropriate topical or systemic antibiotics and antifungals immediately when secondary infections are clinically suspected.

Refractory, extensive, or highly resistant disease requires escalating to advanced therapeutic modalities.
Narrowband ultraviolet B phototherapy serves as an effective intervention.
Systemic immunosuppressive agents become necessary for severe cases failing standard therapy.
Systemic options include daily or monthly bolus systemic corticosteroids, cyclosporine, and azathioprine.